Rocket Pharmaceuticals, Inc. RCKT
2.60
(0.09)
(3.35%)
as of 25 Sep
- Market cap
- $300.8M
- P/E
- 0.0×
Follow RCKT
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (4.77%) | (64.41%) | (60.27%) | (74.88%) |
+8 more TTM periods Free account |
|
| (4.09%) | (55.36%) | (52.00%) | (63.25%) | ||
ROIC |
(114.71%) | (119.39%) | (134.54%) | (141.95%) | |
Return on Tangible Assets |
(6.09%) | (137.74%) | (117.00%) | (106.47%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.51) | (1.60) | (1.71) | (1.82) | |
Free Cash Flow |
(170.39) | (179.79) | (190.45) | (202.78) | |
Capital Expenditures |
(0.13) | (0.17) | (0.44) | (0.67) | |
| Other line items | |||||
Cash ROIC |
(25.34%) | (44.71%) | (39.14%) | (36.36%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.83 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
9.87 | 0.86 | 0.85 | 0.84 | |
Depreciation/Fixed assets |
0.40 | 0.39 | 0.40 | 0.38 | |
Capex/Depreciation |
(0.01) | (0.02) | (0.04) | (0.06) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.51) | (1.60) | (1.71) | (1.81) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates